Article Text

Download PDFPDF
Gender disparities in cardiovascular disease prevention
  1. Lauren E Thompson,
  2. Stacie L Daugherty
  1. Department of Medicine, Divison of Cardiology, University of Colorado School of Medicine, Aurora, USA
  1. Correspondence to Dr Stacie L Daugherty, Department of Medicine, Divison of Cardiology, Univerisity of Colorado School of Medicine, 12401 E 17th Ave, 80045 Aurora CO, USA; Stacie.Daugherty{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Cardiovascular disease (CVD) has historically been viewed as a man’s disease, yet more women than men die from CVD every year.1 Even with national campaigns aimed at increasing awareness of CVD in women, the number of women diagnosed with and dying from CVD continues to increase across the world.1 While biological differences between women and men likely contribute to these differences in outcomes, disparities in cardiovascular care may also play a role. Potential areas in cardiovascular prevention where disparities may occur include inadequate screening, untimely diagnosis and/or lack of appropriate treatment of CVD in women compared with men.

In their Heart paper, Hyun and colleagues evaluated potential gender disparities in cardiovascular risk screening and preventive medication use among patients with high cardiovascular risk enrolled in the Treatment of cardiovascular Risk in Primary care using Electronic Decision suppOrt (TORPEDO) study.2 3 This cluster-randomised trial conducted in 60 Australian primary care practices was designed to test whether an electronic decision support tool improves CVD risk detection and management. Using baseline enrollment data from TORPEDO, the study aimed to evaluate for gender differences in (1) recording of risk factors needed for CVD risk assessment (recorded smoking status, systolic blood pressure (BP) in previous 12 months, total and high density lipoprotein cholesterol in previous 24 months) and (2) appropriate preventive medication use (prescription for one or more BP-lowering drug and a statin for people at high risk without CVD, or a prescription for one or more BP-lowering drugs and a statin and an antiplatelet agent (unless already on an oral anticoagulant) for people with a diagnosis of CVD). High cardiovascular risk was defined by a history of CVD, presence of high risk conditions (diabetes mellitus and age >60 years, diabetes mellitus and albuminuria, stage 3B chronic kidney …

View Full Text


  • Contributors Both authors LET and SLD involved in conception and design, analysis/interpretation of the data, drafting of the manuscript or revising it critically for important intellectual content and review and final approval of the manuscript.

  • Funding SLD has received support from award numbers K08-HL103776 and RO1-HL133343 from the National Heart, Lung and Blood Institute.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles